The FDA issued a warning letter to Revlon citing manufacturing and quality control violations at its Oxford facility.
Its launch raises the question of what impact a new format will have on human workers, as well as on governance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results